利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

3 条记录 (耗时 0.011 秒)

    NOVEL COMPOUNDS
    1.
    发明授权
    NOVEL COMPOUNDS 有权

    公开(公告)号：EP1891056B1

    公开(公告)日：2010-10-13

    申请号：EP06743164.3

    申请日：2006-06-13

    申请人： GLAXO GROUP LIMITED

    发明人： ARISTA, Luca, GlaxoSmithKline SpA ,  BONANOMI, Giorgio, GlaxoSmithKline SpA ,  HAMPRECHT, Dieter, GlaxoSmithKline SpA ,  MICHELI, Fabrizio, GlaxoSmithKline SpA

    IPC分类号： C07D403/12 ,  A61K31/41 ,  A61P25/00

    CPC分类号： C07D403/12

    摘要： The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein G is selected from a group consisting of: phenyl, pyridyl, benzothiazolyl, indazolyl; p is an integer ranging from 0 to 5; R1 is independently selected from a group consisting of: halogen, hydroxy, cyano, C1-4alkyl, halo C1-4alkyl, C1-4alkoxy, halo C1-4alkoxy, C1-4alkanoyl and SF5; or corresponds to a group R5; R2 is hydrogen or C1-4alkyl; R3 is C1-4alkyl; R4 is hydrogen, C1-4alkyl or C1-6 cycloalkyl optionally substituted by 1or 2 substituents selected from the group consisting of: halogen, cyano, C1-4alkyl, halo C1-4alkyl, C1-4alkoxy, C1-4alkanoyl; R5 is a moiety selected from the group consisting of: isoxazolyl, -CH2-N-pyrrolyl, 1,1-dioxido-2-isothiazolidinyl, thienyl, thiazolyl, pyridyl, 2-pyrrolidinonyl, and such a group is optionally substituted by one or two substituents selected from: halogen, cyano, C1-4alkyl, halo C1-4alkyl, C1-4alkoxy, C1-4alkanoyl; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D3 receptors, e.g. to treat drug dependency, or as antipsychotic agents, or to treat obsessive compulsive spectrum disorders or premature ejaculation.

    NOVEL COMPOUNDS
    2.
    发明公开
    NOVEL COMPOUNDS 有权
    新化合物

    公开(公告)号：EP1891056A1

    公开(公告)日：2008-02-27

    申请号：EP06743164.3

    申请日：2006-06-13

    申请人： GLAXO GROUP LIMITED

    发明人： ARISTA, Luca, GlaxoSmithKline SpA ,  BONANOMI, Giorgio, GlaxoSmithKline SpA ,  HAMPRECHT, Dieter, GlaxoSmithKline SpA ,  MICHELI, Fabrizio, GlaxoSmithKline SpA

    IPC分类号： C07D403/12 ,  A61K31/41 ,  A61P25/00

    CPC分类号： C07D403/12

    摘要： The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein G is selected from a group consisting of: phenyl, pyridyl, benzothiazolyl, indazolyl; p is an integer ranging from 0 to 5; R1 is independently selected from a group consisting of: halogen, hydroxy, cyano, C1-4alkyl, halo C1-4alkyl, C1-4alkoxy, halo C1-4alkoxy, C1-4alkanoyl and SF5; or corresponds to a group R5; R2 is hydrogen or C1-4alkyl; R3 is C1-4alkyl; R4 is hydrogen, C1-4alkyl or C1-6 cycloalkyl optionally substituted by 1or 2 substituents selected from the group consisting of: halogen, cyano, C1-4alkyl, halo C1-4alkyl, C1-4alkoxy, C1-4alkanoyl; R5 is a moiety selected from the group consisting of: isoxazolyl, -CH2-N-pyrrolyl, 1,1-dioxido-2-isothiazolidinyl, thienyl, thiazolyl, pyridyl, 2-pyrrolidinonyl, and such a group is optionally substituted by one or two substituents selected from: halogen, cyano, C1-4alkyl, halo C1-4alkyl, C1-4alkoxy, C1-4alkanoyl; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D3 receptors, e.g. to treat drug dependency, or as antipsychotic agents, or to treat obsessive compulsive spectrum disorders or premature ejaculation.

    摘要翻译： 本发明涉及式（I）的新化合物或其药学上可接受的盐，其中G选自：苯基，吡啶基，苯并噻唑基，吲唑基; p是0-5的整数; R1独立地选自卤素，羟基，氰基，C1-4烷基，卤代C1-4烷基，C1-4烷氧基，卤代C1-4烷氧基，C1-4烷酰基和SF5; 或对应于组R5; R2是氢或C1-4烷基; R3是C1-4烷基; R 4是氢，任选被1或2个选自卤素，氰基，C 1-4烷基，卤代C 1-4烷基，C 1-4烷氧基，C 1-4烷酰基的取代基取代的C 1-4烷基或C 1-6环烷基; R5是选自下组的部分：异恶唑基，-CH2-N-吡咯基，1,1-二氧化-2-异噻唑烷基，噻吩基，噻唑基，吡啶基，2-吡咯烷酮基，并且这样的基团任选被一个或 两个选自卤素，氰基，C 1-4烷基，卤代C 1-4烷基，C 1-4烷氧基，C 1-4烷酰基的取代基; 它们的制备方法，用于这些方法的中间体，含有它们的药物组合物以及它们在治疗中的用途，作为多巴胺D3受体的调节剂，例如多巴胺D3受体。 治疗药物依赖，或作为抗精神病药，或治疗强迫性强迫性光谱障碍或早泄。